SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.


Already have an account? Log in here

2seventy Appoints Steven Bernstein as Their New CMO; Susan Abu-Absi Appointed as 2seventy's Chief Technology and Manufacturing Officer

Here is a brief preview of this blast: On Monday, February 14, 2seventy bio announced (press release) the appointment of Steven Bernstein as Chief Medical Officer (CMO) and Susan Abu-Absi as Chief Technology and Manufacturing Officer. Below, Celltelligence provides insights on how 2seventy could leverage Bernstein’s translational clinical background to bring novel assets into the clinic, while discussing the company’s decision to create a Chief Technology and Manufacturing Officer position. 

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.